Mebendazol

Evidensnivå: L5

Förutsagda indikationer: 0 st

---

Innehållsförteckning

1. Mebendazol
2. MEBENDAZOL: Evaluation Hold — Critical Data Gaps Prevent Full Assessment
   1. One-Sentence Summary
   2. Quick Overview
   3. Safety Considerations
   4. Conclusion and Next Steps
   5. Ansvarsfriskrivning

---

## Apotekarens bedömningsrapport

MEBENDAZOL: Evaluation Hold — Critical Data Gaps Prevent Full Assessment

One-Sentence Summary

MEBENDAZOL (mebendazole) is a well-established antiparasitic agent whose original indications and repurposing data could not be retrieved for this assessment. The TxGNN pipeline returned no predicted indications for this compound, and two critical data gaps — TFDA package insert warnings (Blocking severity) and mechanism of action (High severity) — remain unresolved. A full repurposing evaluation cannot be completed at this stage.

---

Quick Overview

Item	Content
Original Indication	Not available in current data pack
Predicted New Indication	No prediction returned
TxGNN Prediction Score	—
Evidence Level	L5 (No predictions; model output absent)
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

---

Safety Considerations

Please refer to the package insert for safety information.

Note: The query log records a successful TFDA package insert retrieval (result_count: 1) and a successful DrugBank lookup (result_count: 1), yet neither safety warnings nor mechanism of action were populated in the Evidence Pack. This suggests a downstream extraction or mapping failure in the pipeline, rather than a true absence of source data.

---

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN predicted indications were returned, and both blocking and high-severity data gaps remain open; without a predicted target indication, mechanism plausibility, or safety baseline, no repurposing case can be constructed or evaluated.

To proceed, the following is needed:

• [DG001 — Blocking] Retrieve TFDA package insert warnings and contraindications: download the insert PDF from the TFDA website and re-run extraction
• [DG002 — High] Populate mechanism of action from the DrugBank API — the query returned 1 result; verify why MOA was not carried through to the Evidence Pack
• Pipeline diagnostic: Confirm that the DrugBank result (result_count: 1) and TFDA insert result (result_count: 1) are being correctly parsed and mapped into drug.original_moa and safety.key_warnings respectively
• Spelling verification: Confirm that the INN query string MEBENDAZOL (without trailing e) matches the canonical WHO INN MEBENDAZOLE in all upstream database lookups, to rule out a name-mismatch causing the TxGNN pipeline to return zero predictions
• Re-run TxGNN: Once the drug identity and MOA fields are correctly populated, re-run the prediction pipeline to obtain ranked predicted indications

  Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.

---